The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...
Eli Lilly is pouring another $4.5 billion into expanding drug manufacturing and development. The diabetes treatment maker ...
Eli Lilly slashed prices for its hugely successful ... offer discounted Zepbound has two benefits. Discounting Zepbound signals the company's commitment to bolster its supply output while ...
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
Eli Lilly (LLY) is reportedly looking to study its weight-loss drug Zepbound in people who aren't considered overweight but ...
As Eli Lilly has surged to become the most valuable company in biopharma—with a market cap now more than twice that of ...
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are ...
The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...